SG149685A1 - Polymer conjugates of neublastin and methods of using same - Google Patents

Polymer conjugates of neublastin and methods of using same

Info

Publication number
SG149685A1
SG149685A1 SG200504719-6A SG2005047196A SG149685A1 SG 149685 A1 SG149685 A1 SG 149685A1 SG 2005047196 A SG2005047196 A SG 2005047196A SG 149685 A1 SG149685 A1 SG 149685A1
Authority
SG
Singapore
Prior art keywords
neublastin
methods
same
polymer conjugates
conjugates
Prior art date
Application number
SG200504719-6A
Other languages
English (en)
Inventor
Dinah W Y Sah
R Blake Pepinsky
Paula Ann Borjack-Sjodin
Stephan S Miller
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of SG149685A1 publication Critical patent/SG149685A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
SG200504719-6A 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same SG149685A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
SG149685A1 true SG149685A1 (en) 2009-02-27

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200504719-6A SG149685A1 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Country Status (35)

Country Link
EP (2) EP1355936B1 (enExample)
JP (2) JP4259868B2 (enExample)
KR (2) KR100960063B1 (enExample)
CN (1) CN1500095B (enExample)
AR (1) AR035077A1 (enExample)
AT (1) ATE365748T1 (enExample)
AU (1) AU2002247037B2 (enExample)
BG (1) BG66393B1 (enExample)
BR (1) BR0206852A (enExample)
CA (1) CA2436407C (enExample)
CY (1) CY1106886T1 (enExample)
CZ (1) CZ20032080A3 (enExample)
DE (1) DE60220879T2 (enExample)
DK (1) DK1355936T3 (enExample)
EA (1) EA009771B1 (enExample)
EE (1) EE05537B1 (enExample)
ES (1) ES2289091T3 (enExample)
GE (1) GEP20063916B (enExample)
HU (1) HU228973B1 (enExample)
IL (2) IL156941A0 (enExample)
IS (1) IS2867B (enExample)
MX (1) MXPA03006805A (enExample)
MY (1) MY143685A (enExample)
NO (1) NO332150B1 (enExample)
NZ (1) NZ527863A (enExample)
PL (1) PL211162B1 (enExample)
PT (1) PT1355936E (enExample)
RS (1) RS50857B (enExample)
SG (1) SG149685A1 (enExample)
SI (1) SI1355936T1 (enExample)
SK (1) SK288123B6 (enExample)
TR (1) TR200301208T2 (enExample)
UA (2) UA100967C2 (enExample)
WO (1) WO2002060929A2 (enExample)
ZA (1) ZA200305733B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
MXPA04006855A (es) * 2002-01-18 2005-04-19 Biogen Idec Inc Compuestos de polimeros de polialquileno y usos de los mismos.
SI1594436T1 (sl) 2003-01-31 2011-01-31 Biogen Idec Inc Mutirani neoblastin
ES2328640T3 (es) 2003-04-18 2009-11-16 Biogen Idec Ma Inc. Neublastina conjugada con un polimero glicosilada.
WO2004108760A2 (en) 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
ATE472333T1 (de) * 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
UA92590C2 (uk) * 2004-08-19 2010-11-25 Байоджен Айдек Ма Інк. Варіанти нейбластину
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
TR201903707T4 (tr) * 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
BR0206852A (pt) * 2001-02-01 2005-05-03 Biogen Inc Conjugados de polìmero de neublastina e métodos para uso dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALOH R H ET AL: "ARTEMIN, A NOVEL MEMBER OF THE GDNF LIGAND FAMILY, SUPPORTS PERIPHERAL AND CENTRAL NEURONS AND SIGNALS THROUGH THE GFRALPHA3- RET RECEPTOR COMPLEX" *
BALOH ROBERT H ET AL: "Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists." *

Also Published As

Publication number Publication date
ES2289091T3 (es) 2008-02-01
BR0206852A (pt) 2005-05-03
YU61003A (sh) 2006-05-25
SK288123B6 (sk) 2013-09-03
EP1862475A1 (en) 2007-12-05
AR035077A1 (es) 2004-04-14
PT1355936E (pt) 2007-09-28
NO20033441D0 (no) 2003-08-01
KR20080098662A (ko) 2008-11-11
DE60220879T2 (de) 2008-03-06
EA200300852A1 (ru) 2004-06-24
GEP20063916B (en) 2006-09-11
MXPA03006805A (es) 2003-11-13
KR100872807B1 (ko) 2008-12-09
IL156941A (en) 2008-11-03
CN1500095B (zh) 2010-06-16
CA2436407C (en) 2011-08-30
SK9712003A3 (en) 2004-01-08
PL211162B1 (pl) 2012-04-30
NO20033441L (no) 2003-10-01
AU2002247037B2 (en) 2007-08-16
DK1355936T3 (da) 2007-10-29
CA2436407A1 (en) 2002-08-08
UA82983C2 (ru) 2008-06-10
EA009771B1 (ru) 2008-04-28
JP4259868B2 (ja) 2009-04-30
ZA200305733B (en) 2005-02-23
IS2867B (is) 2014-02-15
WO2002060929A3 (en) 2003-03-06
JP2005503763A (ja) 2005-02-10
HK1057759A1 (en) 2004-04-16
CY1106886T1 (el) 2012-09-26
NZ527863A (en) 2006-09-29
IS6879A (is) 2003-07-17
SI1355936T1 (sl) 2007-12-31
CN1500095A (zh) 2004-05-26
HU228973B1 (en) 2013-07-29
MY143685A (en) 2011-06-30
HUP0500637A2 (hu) 2005-09-28
EP1355936A2 (en) 2003-10-29
JP4423338B2 (ja) 2010-03-03
IL156941A0 (en) 2004-02-08
ATE365748T1 (de) 2007-07-15
BG108111A (bg) 2004-12-30
UA100967C2 (ru) 2013-02-25
KR20030074766A (ko) 2003-09-19
WO2002060929A2 (en) 2002-08-08
JP2009039135A (ja) 2009-02-26
HUP0500637A3 (en) 2010-01-28
NO332150B1 (no) 2012-07-09
KR100960063B1 (ko) 2010-05-31
EE05537B1 (et) 2012-04-16
CZ20032080A3 (cs) 2003-10-15
BG66393B1 (bg) 2013-11-29
RS50857B (sr) 2010-08-31
DE60220879D1 (de) 2007-08-09
TR200301208T2 (tr) 2005-05-23
PL372101A1 (en) 2005-07-11
EP1355936B1 (en) 2007-06-27
EE200300355A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
SG149685A1 (en) Polymer conjugates of neublastin and methods of using same
EP1196444B8 (en) Exendin-4 conjugates and their medical use
AU7761594A (en) Polyethylene glycols
LTPA2017030I1 (lt) Interferono beta-1A polimero konjugatai ir jų panaudojimas
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
EP1454138A4 (en) IMMUNOCYTOKINS WITH MODULATED SELECTIVITY
WO2003049699A3 (en) Novel monofunctional polyethylene glycol aldehydes
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
ATE331730T1 (de) Neue depsipeptid-verbindung
MXPA05008168A (es) Conjugados de polimero de neublastina mutada.
WO2003040119A8 (fr) Inhibiteurs de l'angiogenese
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
AU2002354872A1 (en) Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents